Drugs / REMINERTANT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00290953 | Oct 2002 → Mar 2006 | small cell lung carcinoma | Sanofi | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REMINERTANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL506981 ↗ |
| Known as | Meclinertant | “Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide” NCT00290953 ↗ |
| Known as | SR-48692 | ChEMBL registry synonym — accepted as the source's own label CHEMBL506981 ↗ |
| Action | Inhibit | “Neurotensin receptor 1 antagonist” CHEMBL506981 ↗ |
| Modality | Small molecule | — CHEMBL506981 ↗ |
| Target | NTSR1 | “Neurotensin receptor 1 antagonist” CHEMBL506981 ↗ |